74. 下垂体性PRL分泌亢進症
[臨床試験数:18,薬物数:33(DrugBank:10),標的遺伝子数:16,標的パスウェイ数:63

Searched query = "Prolactin secreting pituitary adenoma", "Pituitary PRL secretion hyperthyroidism", "Prolactinoma", "Prolactin secreting adenoma"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04107480
(ClinicalTrials.gov)
June 21, 201927/8/2019PRolaCT - Three Prolactinoma RCTsPRolaCT - Three Multicenter Prolactinoma Randomized Clinical TrialsProlactinoma;Prolactin-Producing Pituitary TumorProcedure: Endoscopic trans-sphenoidal adenoma resection;Drug: Dopamine AgonistsLeiden University Medical CenterNULLRecruiting18 YearsN/AAll880Phase 4Netherlands
2NCT03717454
(ClinicalTrials.gov)
December 1, 201814/10/2018Dopamine D2 Receptors(D2R) Imaging in ProlactinomasThe Predictive Value of Positron Emission Tomography-Magnetic Resonance (PET-MR) Mediated Dopamine D2 Receptors Imaging in the Drug Therapy of of Prolactinomas.ProlactinomaOther: Surgery;Drug: Drug treatmentZhebao WuXinqiao Hospital of Chongqing;First Hospital of China Medical University;Beijing Tiantan Hospital;First Affiliated Hospital of Wenzhou Medical University;First Affiliated Hospital of Fujian Medical University;Peking Union Medical College Hospital;Huashan Hospital;Chinese PLA General HospitalNot yet recruiting18 Years65 YearsAll50N/ANULL
3NCT03038308
(ClinicalTrials.gov)
September 16, 201630/1/2017Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist RopiniroleTreatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole: A Dose Escalation Study of Efficacy and TolerabilityHyperprolactinemia;ProlactinomaDrug: RopiniroleColumbia UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruiting18 Years70 YearsAll23Phase 1;Phase 2United States
4NCT03353025
(ClinicalTrials.gov)
January 1, 201620/2/2017Study on Therapy of Non-invasive ProlactinomaProspective Randomized Clinical Study on Transsphenoidal or Dopamine Drugs Therapy Treat Non-invasive ProlactinomaProlactinomaProcedure: transsphenoidal surgery treatment;Drug: dopamine agonist treatmentFirst Affiliated Hospital, Sun Yat-Sen UniversityNULLRecruiting18 Years60 YearsAll394N/AChina
5NCT01620138
(ClinicalTrials.gov)
March 201018/9/2011Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant ProlactinomasSomatostatin and Dopamine Receptors Expression in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vitro and in Vivo Responsiveness to Somatostatin Analogs and Dopamine AgonistNon-functioning Pituitary Adenomas;ProlactinomasDrug: Pasireotide;Drug: cabergolineUniversidade Federal do Rio de JaneiroNULLCompleted18 YearsN/AAll21Phase 2;Phase 3Brazil